Butterfly Network Launches iQ + Vet Ultrasound, the Next Big Change in Veterinary Medicine, with International Expansion and New Partners
GUILFORD, Connecticut & NEW YORK – (COMMERCIAL THREAD) – Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), an innovative digital health company that strives to democratize medical imaging and improve equity in global health, ushers in the next big change in veterinary medicine with the launch of the new Butterfly iQ + Vet. The second-generation device brings sharper imaging, a new procedural guidance tool, and hardware enhancements that make the solution more powerful, versatile and easier to use.
“Veterinarians provide incredible care and face the unique challenge of serving patients who cannot speak,” said Todd Fruchterman, MD, PhD, President and CEO of Butterfly. “They need clinical information at their fingertips to help them make more informed decisions and effectively achieve positive patient outcomes. This is where Butterfly iQ + Vet comes in: we are creating a new shift in care focused on acquiring crucial information from inside the body that our system enables us to use in real time.
iQ + Vet has been carefully designed to powerfully serve veterinarians in a variety of healthcare settings.
Crisp imagery, quick responses
Over 800 hours of engineering work dedicated to optimizing veterinarian-specific clinical presets has dramatically improved imaging in all applications. iQ + Vet is equipped with a suite of powerful new features such as color Doppler sensitivity and increased maximum depth, helping vets collect the image they need to provide more informed care.
The innovative Needle Viz ™ tool is now available to veterinarians in five clinical presets (Bladder, MSK, Equine MSK, Small Organ and Vascular). The ability to view the needles in the plane will help vets perform fine needle aspirations with more confidence and quickly place lines and injections with greater certainty in emergency care situations.
Ease of use
Hardware and software enhancements now allow veterinarians to take full advantage of the diagnostic power of iQ + Vet. A 15% smaller probe face and 10% shorter probe make maneuvering easier during a wide variety of scans. Up to 20% increase in battery life and improved continuous run time before thermal shutdown ensures that the iQ + Vet runs even longer in the clinic or in the field. Butterfly’s veterinary software now includes customizable worksheets, which help users enter the precise information needed for each patient.
Compatibility and pricing flexibility
Now compatible with Android and the option of a USB-C or Lightning cable, iQ + Vet introduces a whole new group of veterinarians and practices to the diagnostic power of portable ultrasound. Additionally, Butterfly has introduced flexible pricing options to meet the needs of veterinary clients in a variety of care settings, including rental and outright purchase options.
Global expansion and partnerships
With the new value offered by the device and growing global demand, Butterfly has now made iQ + Vet available for purchase in 19 new international markets: Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland and United Kingdom.
International expansion has enabled exciting new partnerships. Butterfly expands its collaboration with MWI Animal Health, a leading distributor of animal health products and services. MWI UK will support the distribution of Butterfly iQ + Vet to veterinary practices in the UK. Butterfly is also launching a new partnership in Australia and New Zealand with REM SYSTEMS, which is part of the Paragon Care group, an established veterinary distributor. These are important first steps in growing Butterfly’s veterinary presence outside of the United States.
In the United States, Butterfly is increasing its impact with the announcement of a large-scale innovation partnership with Rarebreed Veterinary Partners, a strategic partner that develops and supports veterinary clinics in the eastern United States. Rarebreed will deploy iQ + Vet system-wide in its innovative community of veterinary practice.
“Rarebreed is thrilled to partner with Butterfly to make ultrasound accessible to more patients,” said Dan Espinal, co-founder and CEO of Rarebreed. “Rarebreed exists to improve the quality of care throughout the profession and bring innovation to the practices of our partners. Ultrasound should be an integral part of almost all diagnostic tests.
“Our partnership with Rarebreed to deploy iQ + Vet system-wide is a prime example of recognizing the potential and impact of iQ + Vet for best veterinary practices to improve the care they provide,” said Darius Shahida, director of strategy and business development for Butterfly Network. “Not only will Rarebreed vets integrate this powerful diagnostic tool into their practices to provide new and faster information, but this deployment will also strengthen the bond these vets have with their pet owners who seek the best care for their animals. of company. ”
By establishing such partnerships and increasing access to this diagnostic solution, Butterfly has the potential to advance veterinary medicine. The powerful, multi-species and easy-to-use imaging solution will help veterinarians around the world take advantage of diagnostic opportunities and provide more efficient care.
Butterfly will host a virtual launch event on October 5, 2021 at 5 p.m. EDT to share more details. Reserve your spot today on the Butterfly veterinary website. Butterfly iQ + Vet will be available for sale online in geographies where the product is commercially available by the end of the day.
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011 and recently listed on the NYSE through a merger with Longview Acquisition Corp (NYSE: BFLY), Butterfly Network is the creator of the world’s most advanced single-probe portable veterinary ultrasound system, Papillon iQ + Veterinary. Butterfly’s mission is to enable universal access to superior medical imaging, and part of that mission is to enable scanning of every animal at every vet visit. Thanks to its exclusive on-chip ultrasoundMT technology, Butterfly paves the way for earlier detection and remote management of global health problems. The Butterfly iQ + Vet can be purchased online by practicing veterinarians in approved countries in the store or by contacting sales at [email protected]
About rare breeds
Rarebreed Veterinary Partners is a thriving veterinary hospital community that goes the extra mile to create exceptional work experiences, one partnership or one team member at a time. We pride ourselves on building trusting and lasting relationships with our partner hospitals, with the goal of providing exceptional patient care, exceptional customer service and an incredible work experience. We continue to build a vast network of practices that enhance healthcare teams by offering them the innovation and tools necessary to develop, improve and reinvent the veterinary experience. For more information, visit www.rarebreedvet.com.
This press release includes “forward-looking statements” within the meaning of the “safety regulations” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates and projections and, accordingly , you should not rely on these forward-looking statements as predictions of future events. Words such as “expect”, “estimate”, “project”, “budget”, “plan”, “anticipate”, “intend”, “plan”, “can”, “will” , “Could”, “should,” “believe”, “predict”, “potential”, “continue” and similar expressions (or negative versions of such words or phrases) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations regarding the future performance and development of products and services. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are beyond the control of the Company and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company’s business; the ability to recognize the anticipated benefits of the business combination; the Company’s ability to grow and manage its growth profitably; the success, cost and timing of the Company’s product and service development activities; the attributes and potential benefits of the Company’s products and services; the Company’s ability to obtain and maintain regulatory approval for its products, and all related restrictions and limitations of any approved product; the Company’s ability to identify, license or acquire additional technology; the Company’s ability to maintain its existing licensing, manufacturing, supply and distribution agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; changes in applicable laws or regulations; the size and growth potential of markets for the Company’s products and services, and its ability to serve these markets, alone or in partnership with others; the pricing of the Company’s products and services and the reimbursement of medical acts performed using its products and services; the Company’s estimates of expenses, income, capital requirements and additional financing requirements; the financial performance of the Company; the Company’s ability to raise financing in the future; and other risks and uncertainties indicated from time to time in documents filed by the Company with the Securities and Exchange Commission. The Company cautions that the above list of factors is not exclusive. The Company cautions you not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. The Company does not undertake or accept any obligation or undertake to publish any update or revision of any forward-looking statement to reflect any change in the expectations of the Company or any change in events, conditions or circumstances on on which such a statement is based.